Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 Diabetes

Several immunotherapies have demonstrated endogenous insulin preservation in recent-onset type 1 diabetes (T1D). We considered the primary results of rituximab, abatacept, teplizumab, alefacept, high-dose antithymocyte globulin (ATG), low-dose ATG, and low-dose ATG ± granulocyte-colony–stimulating f...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacobsen, Laura M., Bundy, Brian N., Greco, Madison N., Schatz, Desmond A., Atkinson, Mark A., Brusko, Todd M., Mathews, Clayton E., Herold, Kevan C., Gitelman, Stephen E., Krischer, Jeffrey P., Haller, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2020
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7757538/
https://www.ncbi.nlm.nih.gov/pubmed/32833543
http://dx.doi.org/10.1089/dia.2020.0305

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7757538/
https://www.ncbi.nlm.nih.gov/pubmed/32833543
http://dx.doi.org/10.1089/dia.2020.0305

Ejemplares similares